Abstract 178P
Background
The emergence of immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway has revolutionized cancer treatment, resulting in significantly improved clinical outcomes. However, resistance mechanisms remain a critical challenge.
Methods
This study aimed to elucidate immunophenotypic changes in syngeneic mouse models sensitive (MC-38) or resistant (LLC1) to anti-PD-1 monoclonal antibody (mAb) treatment. Flow cytometry analysis was performed to unravel significant alterations in immune cell populations within tumor microenvironments (TME) and tumor-draining lymph nodes (TdLNs).
Results
In the MC-38 model, anti-PD-1 mAb treatment led to increased dendritic cells (DCs) and macrophages, while decreasing myeloid-derived suppressor cells (MDSCs) in tumors. Upregulation of antigen presentation molecules (MHC class I and II) and immune checkpoint or functional molecules (CD80, CD86, CCR7, PD-L1) was observed on tumor-associated DCs and macrophages. Additionally, significant increases in tumor-infiltrating CD4+ T cells, CD8+ T cells, especially TCM and TEM cells, regulatory T cells, NK cells, and NKT cells were noted. Importantly, the treatment enhanced cytotoxic potential of various lymphocytes, with perforin emerging as the most reliable marker associated with treatment efficacy. Correlation analysis revealed strong negative associations between tumor volume and perforin-expressing CD4+ T cells and NKT cells. Conversely, the LLC1 model showed minimal immunophenotypic changes upon anti-PD-1 mAb treatment.
Conclusions
These findings provide comprehensive insights into the immune landscape modifications induced by anti-PD-1 mAb therapy and identify key immunological markers such as perforin, particularly in CD4+ T cells and NKT cells, and DC/MDSCs ratios that may predict therapeutic outcomes. This study offers insights into the predictive biomarkers and potential combination strategies for enhancing the efficacy of PD-1-targeted immunotherapy in resistant tumors.
Legal entity responsible for the study
Shin Nippon Biomedical Laboratories.
Funding
Shin Nippon Biomedical Laboratories.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
109P - Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
Presenter: Mengxing You
Session: Poster Display session
Resources:
Abstract
110P - Safety and effectiveness of adebrelimab as first-line treatment in extensive-stage small-cell lung cancer: A prospective, real-world study
Presenter: Junxu Wen
Session: Poster Display session
Resources:
Abstract
111P - Real-world treatment patterns and clinical outcomes in Chinese stage III non-small cell lung cancer (NSCLC) patients: Results of MOOREA study
Presenter: Ligang Xing
Session: Poster Display session
Resources:
Abstract
112P - Serplulimab combined with chemotherapy and anlotinib for extensive-stage small-cell lung cancer: A multicenter real-world experience
Presenter: Jun Wang
Session: Poster Display session
Resources:
Abstract
113P - Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: An observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
Presenter: Irene Torresan
Session: Poster Display session
Resources:
Abstract
114P - Cadonilimab plus chemotherapy as first-line (1L) treatment for metastatic gastric (G) or gastroesophageal junction adenocarcinoma (GEJA) with PD-L1 CPS=5: Updated results from a real-world study
Presenter: Qi Xu
Session: Poster Display session
Resources:
Abstract
115P - Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors in Germany: A population-based study
Presenter: Lucie Heinzerling
Session: Poster Display session
Resources:
Abstract
116TiP - An umbrella trial (RECHALLENGE) to evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumor patients after disease progression in clinical trials
Presenter: Huilei Miao
Session: Poster Display session
Resources:
Abstract
122P - Intracellular adenosine drives profound lymphocyte suppression and can be reversed with EOS-984: A potent ENT1 antagonist
Presenter: Erica Houthuys
Session: Poster Display session
Resources:
Abstract
123P - Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD1 inhibition in preclinical models of CLDN18.2-expressing cancers
Presenter: Thomas O'Hare
Session: Poster Display session
Resources:
Abstract